284 related articles for article (PubMed ID: 35983569)
21. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract][Full Text] [Related]
22. Adult-onset eosinophilic airway diseases.
Asano K; Ueki S; Tamari M; Imoto Y; Fujieda S; Taniguchi M
Allergy; 2020 Dec; 75(12):3087-3099. PubMed ID: 33040364
[TBL] [Abstract][Full Text] [Related]
23. Experimental Modeling of Eosinophil-Associated Diseases.
Upparahalli Venkateshaiah S; Manohar M; Kandikattu HK; Mishra A
Methods Mol Biol; 2021; 2241():275-291. PubMed ID: 33486743
[TBL] [Abstract][Full Text] [Related]
24. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
25. Anti-IL5 therapy for asthma and beyond.
Mukherjee M; Sehmi R; Nair P
World Allergy Organ J; 2014; 7(1):32. PubMed ID: 25709744
[TBL] [Abstract][Full Text] [Related]
26. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
27. Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis.
Syverson EP; Hait E
Gastroenterol Hepatol (N Y); 2022 Apr; 18(4):207-212. PubMed ID: 35505944
[TBL] [Abstract][Full Text] [Related]
28. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
29. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
30. Biologic therapies targeting eosinophils: current status and future prospects.
Legrand F; Klion AD
J Allergy Clin Immunol Pract; 2015; 3(2):167-74. PubMed ID: 25754717
[TBL] [Abstract][Full Text] [Related]
31. Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders.
Shukla A; Mishra A; Venkateshaiah SU; Manohar M; Mahadevappa CP; Mishra A
J Genet Syndr Gene Ther; 2015 Aug; 6(2):. PubMed ID: 27840774
[TBL] [Abstract][Full Text] [Related]
32. The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs.
Ridolo E; Barone A; Ottoni M; Peveri S; Montagni M; Nicoletta F
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338983
[TBL] [Abstract][Full Text] [Related]
33. Treatments of refractory eosinophilic lung diseases with biologics.
Asano K; Suzuki Y; Tanaka J; Kobayashi K; Kamide Y
Allergol Int; 2023 Jan; 72(1):31-40. PubMed ID: 36333218
[TBL] [Abstract][Full Text] [Related]
34. Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis.
Tanaka S; Tsuji T; Shiotsu S; Yuba T; Hiraoka N
Cureus; 2022 May; 14(5):e25218. PubMed ID: 35747049
[TBL] [Abstract][Full Text] [Related]
35. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
36. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
37. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
[TBL] [Abstract][Full Text] [Related]
38. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
Ko E; Chehade M
Clin Rev Allergy Immunol; 2018 Oct; 55(2):205-216. PubMed ID: 29372536
[TBL] [Abstract][Full Text] [Related]
39. Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.
Dellon ES; Simon D; Wechsler ME
J Allergy Clin Immunol Pract; 2022 May; 10(5):1169-1176. PubMed ID: 35167955
[TBL] [Abstract][Full Text] [Related]
40. [Eosinophilic granulomatosis with polyangiitis (EGPA) and allergic bronchopulmonary mycosis (ABPM)].
Taniguchi M; Fukutomi Y
Nihon Rinsho; 2016 Oct; 74(10):1721-1728. PubMed ID: 30551287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
